Skip to content

Fast-track Perioperative Program for Laparoscopic Colorectal Surgery

The Impact of Fast-track Perioperative Program on the Clinical and Immunological Outcomes After Laparoscopic Colorectal Surgery in Hong Kong Chinese Patients: A Prospective Randomized Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01341366
Enrollment
128
Registered
2011-04-25
Start date
2010-11-30
Completion date
2013-03-31
Last updated
2013-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Laparoscopic surgery

Brief summary

Background: Laparoscopic colorectal surgery has been shown by randomized trials to be associated with better short-term clinical outcomes when compared with open surgery. However, in a traditional perioperative care setting, the reduction in hospital stay following laparoscopic surgery in these trials was modest. Fast-track perioperative programs have been introduced in the West to optimize perioperative factors to reduce the physiological/psychological stress of open colorectal surgery. However, few studies have evaluated the impact of fast-track programs on the outcomes after laparoscopic colorectal surgery. Objective: To compare the clinical and immunological outcomes of Hong Kong Chinese patients undergoing laparoscopic surgery for colorectal cancer with a traditional vs. a fast-track perioperative program. Design: Prospective randomized trial. Subjects: One hundred and twenty-eight consecutive patients undergoing elective laparoscopic resection of non-metastatic colonic and upper rectal cancer will be recruited. Interventions: Patients will be randomized to a traditional or a fast-track perioperative program. Outcome measures: Primary outcome: total postoperative hospital stay, including hospital stay of patients who are readmitted within 30 days after surgery. Secondary outcomes: immunological parameters (including systemic cytokine response and cell-mediated immune function), morbidity and mortality, quality of life, and medical costs.

Interventions

Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization

OTHERTraditional perioperative program

Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Consecutive patients undergoing elective laparoscopic resection of colonic and upper rectal cancer, * Age of patients between 18 and 75 years * Patients with American Society of Anesthesiologists grading I-II * Patients with no severe physical disability * Patients who require no assistance with the activities of daily living * Informed consent available

Exclusion criteria

* Patients undergoing laparoscopic low anterior resection with total mesorectal excision, abdominoperineal resection, or total/proctocolectomy * Patients with planned stoma creation * Patients undergoing emergency surgery * Patients with known metastatic disease * Patients with previous history of abdominal surgery * Patients with known immunological dysfunction * Patients who are taking steroids or immunosuppressive agents * Patients with chronic pain syndrome

Design outcomes

Primary

MeasureTime frameDescription
Duration of hospital stayUp to 1 monthTotal postoperative hospital stay, including hospital stay of patients who are readmitted within 30 days after surgery.

Secondary

MeasureTime frameDescription
Direct/indirect medical costs and out-of-hospital economic costsUp to 1 month
Systemic cytokine responsesUp to 1 weekBlood levels of IL-1β, IL-6, and C-reactive protein
Pain scoresUp to 1 weekPain scores on visual analogue scale (from 0 which implies no pain at all, to 100 which implies the worst pain imaginable)
Quality of lifeUp to 1 monthMeasured by SF-36, EORTC QLQ-C30 and QLQ-CR38 questionnaires
Readmission rateUp to 1 month
Lymphocyte subsetsUp to 1 weekUsing flow cytometer to determine lymphocyte subsets and NK cell counts (cells/uL)
Morbidity and mortalityUp to 1 month

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026